A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, were associated with fewer hospitalisations among individuals with alcohol use disorder, AUD. Fewer hospitalisations were observed for alcohol related …
